Estradiol & medroxyprogesterone acetate
ApprovedSmall molecule
Estradiol & medroxyprogesterone acetate is one of 50 small molecule programs targeting Lower Urinary Tract Symptom. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
150 competitors in Overactive Bladder
#DrugCompanyPhaseTrials
1Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Neurontin
VViatris Specialty LLC
Phase 3
Botox
AbbViePhase 3
GSK1358820
GSKPhase 3
Tolterodine PR
PfizerPhase 3
Estradiol & medroxyprogesterone acetate
FFar Eastern Memorial Hospital
Approved
Oxybutynin Chloride
Mylan Pharmaceuticals IncPhase 3
Vesicare
AstellasPhase 3
YM178
AstellasPhase 3
SPM 907
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- FFar Eastern Memorial Hospital